

HR 8289

Banning Misleading Drug Ads Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 5, 2022

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Jul 5, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/8289>

Sponsor

Name: Rep. Spanberger, Abigail Davis [D-VA-7]

Party: Democratic • **State:** VA • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Axne, Cynthia [D-IA-3]	D · IA		Jul 5, 2022
Rep. Craig, Angie [D-MN-2]	D · MN		Jul 5, 2022
Rep. Porter, Katie [D-CA-45]	D · CA		Jul 5, 2022
Rep. Wild, Susan [D-PA-7]	D · PA		Jul 5, 2022
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Oct 31, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Jul 5, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jul 5, 2022)

Banning Misleading Drug Ads Act of 2022

This bill finalizes a 2010 proposed rule from the Food and Drug Administration (FDA) regarding television and radio prescription drug advertisements if the FDA does not otherwise issue a final rule within 180 days of the bill's enactment. (The proposed rule specifies standards for major statements about a drug's side effects in television and radio advertisements.)

Actions Timeline

- **Jul 5, 2022:** Introduced in House
- **Jul 5, 2022:** Referred to the House Committee on Energy and Commerce.